Verona Pharma PLC
NASDAQ:VRNA
Verona Pharma PLC
NASDAQ:VRNA
Price:
53.52
USD
-7.87%
Market Cap:
4.6B
USD
Income Statement
Earnings Waterfall
Verona Pharma PLC
Verona Pharma PLC
|
Revenue
|
42.3m
USD
|
|
Cost of Revenue
|
-2.6m
USD
|
|
Gross Profit
|
39.7m
USD
|
|
Operating Expenses
|
-194.3m
USD
|
|
Operating Income
|
-154.6m
USD
|
|
Other Expenses
|
-18.8m
USD
|
|
Net Income
|
-173.4m
USD
|
Income Statement
Verona Pharma PLC
Verona Pharma PLC
Currency: USD
Millions
TTM
| Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
40
N/A
|
40
N/A
|
40
N/A
|
40
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
6
N/A
|
42
+652%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(3)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
5
N/A
|
40
+681%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||
| Operating Expenses |
(9)
|
(14)
|
(24)
|
(31)
|
(38)
|
(48)
|
(45)
|
(43)
|
(34)
|
(36)
|
(58)
|
(70)
|
(52)
|
(63)
|
(55)
|
(62)
|
(74)
|
(87)
|
(94)
|
(100)
|
(113)
|
(116)
|
(107)
|
(89)
|
(76)
|
(74)
|
(64)
|
(65)
|
(68)
|
(73)
|
(131)
|
(160)
|
(194)
|
|
| Selling, General & Administrative |
(3)
|
(5)
|
(7)
|
(9)
|
(8)
|
(10)
|
(9)
|
(8)
|
(8)
|
(9)
|
(12)
|
(13)
|
(10)
|
(16)
|
(17)
|
(25)
|
(30)
|
(34)
|
(35)
|
(35)
|
(34)
|
(32)
|
(30)
|
(24)
|
(27)
|
(29)
|
(36)
|
(44)
|
(50)
|
(61)
|
(98)
|
(120)
|
(150)
|
|
| Research & Development |
(6)
|
(10)
|
(16)
|
(23)
|
(30)
|
(39)
|
(36)
|
(35)
|
(26)
|
(27)
|
(46)
|
(57)
|
(42)
|
(48)
|
(39)
|
(37)
|
(45)
|
(54)
|
(59)
|
(65)
|
(79)
|
(83)
|
(78)
|
(65)
|
(49)
|
(44)
|
(30)
|
(24)
|
(17)
|
(15)
|
(33)
|
(41)
|
(45)
|
|
| Depreciation & Amortization |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
2
|
0
|
4
|
0
|
0
|
0
|
|
| Operating Income |
(9)
N/A
|
(14)
-56%
|
(24)
-63%
|
(31)
-33%
|
(38)
-22%
|
(48)
-26%
|
(45)
+7%
|
(43)
+4%
|
(34)
+21%
|
(36)
-5%
|
(58)
-61%
|
(70)
-21%
|
(52)
+26%
|
(63)
-21%
|
(55)
+13%
|
(62)
-11%
|
(74)
-21%
|
(87)
-18%
|
(94)
-8%
|
(60)
+36%
|
(73)
-22%
|
(76)
-3%
|
(67)
+11%
|
(89)
-32%
|
(76)
+15%
|
(74)
+3%
|
(63)
+14%
|
(64)
-2%
|
(68)
-5%
|
(73)
-7%
|
(131)
-81%
|
(155)
-19%
|
(155)
+0%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||
| Interest Income Expense |
1
|
4
|
8
|
6
|
6
|
(8)
|
(5)
|
2
|
2
|
17
|
12
|
10
|
3
|
2
|
(0)
|
(2)
|
1
|
0
|
2
|
3
|
2
|
2
|
(4)
|
(6)
|
(2)
|
3
|
9
|
13
|
13
|
11
|
9
|
3
|
(8)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
(4)
|
(4)
|
(4)
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
9
|
9
|
9
|
8
|
8
|
10
|
15
|
21
|
16
|
15
|
16
|
14
|
10
|
11
|
3
|
1
|
1
|
(1)
|
2
|
4
|
4
|
|
| Pre-Tax Income |
(8)
N/A
|
(11)
-31%
|
(15)
-45%
|
(25)
-66%
|
(32)
-29%
|
(57)
-75%
|
(51)
+11%
|
(42)
+18%
|
(32)
+23%
|
(19)
+40%
|
(46)
-138%
|
(61)
-32%
|
(40)
+33%
|
(52)
-28%
|
(47)
+10%
|
(56)
-20%
|
(65)
-16%
|
(77)
-18%
|
(77)
+0%
|
(37)
+52%
|
(56)
-50%
|
(59)
-6%
|
(55)
+7%
|
(82)
-49%
|
(68)
+16%
|
(60)
+12%
|
(51)
+15%
|
(50)
+2%
|
(54)
-8%
|
(62)
-16%
|
(124)
-98%
|
(152)
-23%
|
(163)
-7%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||
| Tax Provision |
1
|
2
|
3
|
5
|
6
|
8
|
7
|
7
|
6
|
6
|
10
|
12
|
(0)
|
1
|
(1)
|
(2)
|
(0)
|
(1)
|
(5)
|
(8)
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(1)
|
(2)
|
(2)
|
(10)
|
|
| Income from Continuing Operations |
(7)
|
(8)
|
(12)
|
(21)
|
(26)
|
(49)
|
(43)
|
(34)
|
(27)
|
(13)
|
(36)
|
(48)
|
(41)
|
(51)
|
(48)
|
(58)
|
(65)
|
(78)
|
(81)
|
(45)
|
(56)
|
(59)
|
(55)
|
(82)
|
(69)
|
(61)
|
(52)
|
(51)
|
(54)
|
(63)
|
(125)
|
(154)
|
(173)
|
|
| Net Income (Common) |
(7)
N/A
|
(8)
-25%
|
(12)
-41%
|
(21)
-73%
|
(26)
-28%
|
(49)
-87%
|
(43)
+12%
|
(34)
+21%
|
(27)
+23%
|
(13)
+51%
|
(36)
-174%
|
(48)
-34%
|
(41)
+16%
|
(51)
-25%
|
(48)
+6%
|
(58)
-22%
|
(65)
-13%
|
(78)
-20%
|
(81)
-4%
|
(45)
+45%
|
(56)
-24%
|
(59)
-6%
|
(55)
+7%
|
(82)
-49%
|
(69)
+16%
|
(61)
+12%
|
(52)
+15%
|
(51)
+2%
|
(54)
-7%
|
(63)
-17%
|
(125)
-98%
|
(154)
-23%
|
(173)
-13%
|
|
| EPS (Diluted) |
0
N/A
|
-0.1
N/A
|
-0.19
-90%
|
-0.19
N/A
|
-0.3
-58%
|
-0.46
-53%
|
-0.4
+13%
|
-0.32
+20%
|
-0.25
+22%
|
-0.13
+48%
|
-0.35
-169%
|
-0.47
-34%
|
-0.39
+17%
|
-0.5
-28%
|
-0.16
+68%
|
-0.3
-88%
|
-0.25
+17%
|
-0.16
+36%
|
-0.17
-6%
|
-0.08
+53%
|
-0.12
-50%
|
-0.13
-8%
|
-0.12
+8%
|
-0.14
-17%
|
-0.13
+7%
|
-0.09
+31%
|
-0.09
N/A
|
-0.08
+11%
|
-0.09
-13%
|
-0.1
-11%
|
-0.19
-90%
|
-0.24
-26%
|
-0.27
-13%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
